poisar

Stocks · News reference

SRX Global Activates UC Davis as Clinical Trial Site for CERo Therapeutics' CER-1236 Study

Fiscal.ai

SRX Global announced that the University of California, Davis has been activated as a clinical trial site for the ongoing Phase 1 CERTAIN-T study of CER-1236.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

    SRX Global commented on industry activity in engineered T-cell therapies following Pfizer's $330 million upfront deal with Starna Therapeutics for pre-IND CAR-T programs. SRX is proceeding with its pending acquisition of CERo Therapeutics, which is advancing CER-1236, a clinical-stage engineered T-cell therapy currently in Phase 1/1b CERTAIN-T trials with seven patients dosed and no dose-limiting toxicities reported.